deltatrials
Completed PHASE3 NCT00001812

A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Impact of Nystatin on the Development of Oral Irritation in Patients Receiving High Dose Intravenous Interleukin-2

Sponsor: National Cancer Institute (NCI)

Conditions Candidiasis, Oral Gastrointestinal Diseases Stomatitis
Interventions Nystatin
Updated 5 times since 2017 Last updated: Mar 3, 2008 Started: Apr 30, 1999 Completion: Aug 31, 2000

This PHASE3 trial investigates Candidiasis, Oral and Gastrointestinal Diseases and is currently completed. National Cancer Institute (NCI) leads this study, which shows 5 recorded versions since 1999 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Apr 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Bethesda, United States